Department of Medicine/Nephrology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA.
Curr Opin Endocrinol Diabetes Obes. 2016 Dec;23(6):423-429. doi: 10.1097/MED.0000000000000294.
This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease.
FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality.
Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.
本综述探讨了成纤维细胞生长因子 23（FGF-23）与心血管疾病之间的关联。
FGF-23 是一种由骨细胞和成骨细胞产生的激素，有助于肾脏排磷，并作为活性维生素 D 合成的负反馈调节剂。最近的研究发现，升高的 FGF-23 水平与多种心血管疾病之间存在关联，包括高血压、左心室肥厚、内皮功能障碍、心血管事件和死亡率。
最近的研究探讨了 FGF-23 对心血管系统的可能影响。在动物和观察性人体研究中，升高的 FGF-23 水平与多种心血管结局之间存在关联，包括高血压、左心室肥厚和心血管事件及死亡率。需要进一步研究来评估降低 FGF-23 水平是否能改善心血管结局。
